Skip to main content

GLP-1 Receptor Agonists Tied to Decrease in T2DM-Related Dementia Risk

Medically reviewed by Carmen Pope, BPharm. Last updated on July 23, 2025.

via HealthDay

WEDNESDAY, July 23, 2025 -- Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin, according to a study published online July 22 in BMJ Open Diabetes Research & Care.

Mingyang Sun, from the People's Hospital of Zhengzhou University in China, and colleagues conducted a retrospective cohort study using data from a global health research network between 2004 and 2024 to examine the comparative effectiveness of GLP-1 RAs and metformin in reducing dementia risk. Patients with T2DM initiating GLP-1 RAs or metformin as first-line monotherapy were included (87,229 matched patients per cohort).

The researchers found that compared with metformin, GLP-1 RA use was associated with a significantly lower risk for overall dementia, Alzheimer disease, and nonvascular dementias (adjusted hazard ratios, 0.90, 0.88, and 0.75, respectively). For vascular dementia, no significant difference was observed. Consistent benefit was seen across age and sex in subgroup analyses, with the strongest effect seen among older adults and women.

"Despite limitations such as residual confounding, the findings remain robust and suggest GLP-1 RAs could redefine T2DM-related dementia prevention strategies, warranting further randomized controlled trials to confirm these results," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

Metabolic Surgery Has Greater Long-Term Benefits Than GLP-1 Receptor Agonists

WEDNESDAY, Oct. 1, 2025 -- People with obesity and type 2 diabetes who undergo metabolic surgery live longer and face fewer serious health problems compared with patients treated...

Skin-to-Skin Contact Boosts Brain Growth in Very Preterm Infants

WEDNESDAY, Oct. 1, 2025 -- Skin-to-skin contact is linked to brain growth in very preterm infants, according to a study published online Sept. 24 in Neurology. Katherine E...

Self-Reported Cognitive Disability Rates Increased in U.S. Adults From 2013 to 2023

TUESDAY, Sept. 30, 2025 -- Rates of self-reported cognitive disability rose in U.S. adults from 5.3 to 7.4 percent in the last decade, particularly among younger adults, according...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.